About Us
IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company’s AI based process to provide healthcare professionals with decision support in the assessment of various medical conditions.
PressureSafe, the company’s first product based on this platform, is a handheld device designed to revolutionize the assessment of pressure injuries (PI) affecting skin and underlying tissue. Pressure Injury in the US alone accounts for $26.8B in healthcare spending and results in 60,000 deaths annually. PressureSafe is expected to contribute to assessment of pressure injuries, regardless of patient skin tone. This will drive equitable healthcare and help reduce the toll and cost of PI.
IR-MED holds patents protecting its innovation in noninvasive tissue assessment
Our Team
Oded Bashan
Chairman
Aharon Binur
Chief Development Officer
Sharon Levkoviz
Chief Financial Officer
Dr. Yaniv Cohen
Co-Founder & CSO
Yoram Drucker
VP Business Development
Awards
Tech 2024-Best Up-and-Coming Health Tech Company
We are thrilled to announce that IR-MED Sensing the Invisible- platform has won a Netty Award for the category
Tech (Best Up-and-Coming Health Tech Company)
The exceptional work has set IRMED apart in a field of remarkable entries, truly embodying the spirit of creativity, innovation, and technical proficiency that the Netty Awards celebrates.
The Netty Awards celebrate achievements in the digital landscape, honoring top companies and leaders. It sets a benchmark for excellence and is a testament to the creativity, innovation, and technical prowess demonstrated by the winners.
Most Innovative Non-Invasive Diagnostics Technology Developer 2023 – Israel
IR-Med Inc. has been recognized as the Most Innovative Non-Invasive Diagnostics Technology Developer 2023 – Israel. Certainly, with its
PressureSafe device alone it has the potential to significantly improve care for patients and improve healthcare equity overall.
